YU2000A - Farmaceutski preparat koji sadrži atorvastatin i antihipertenzivni agens - Google Patents
Farmaceutski preparat koji sadrži atorvastatin i antihipertenzivni agensInfo
- Publication number
- YU2000A YU2000A YU2000A YU2000A YU2000A YU 2000 A YU2000 A YU 2000A YU 2000 A YU2000 A YU 2000A YU 2000 A YU2000 A YU 2000A YU 2000 A YU2000 A YU 2000A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- atorvastatin
- combinations
- combination therapy
- antihypertensive agent
- hyperlipidemia
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title abstract 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title abstract 3
- 229940030600 antihypertensive agent Drugs 0.000 title abstract 3
- 239000002220 antihypertensive agent Substances 0.000 title abstract 3
- 229960005370 atorvastatin Drugs 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 2
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 2
- 230000000747 cardiac effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 239000011885 synergistic combination Substances 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
Abstract
Ovaj pronalazak se odnosi na farmaceutske kombinacije atorvastatina ili njegove farmaceutski prihvatljive soli i antihipertenzivnih agenasa. Ovaj pronalazak se, takodje, odnosi na aditive i sinergističke kombinacije atorvastatina ili njegove farmaceutski prihvatljive soli.[This invention relates to pharmaceutical combinations of atorvastatin or a pharmaceutically acceptable salt thereof and antihypertensive agents, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of atorvastatin or a pharmaceutically acceptable salt thereof and antihypertensive agents whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5727697P | 1997-08-29 | 1997-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU2000A true YU2000A (sh) | 2002-12-10 |
Family
ID=22009602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU2000A YU2000A (sh) | 1997-08-29 | 1998-08-11 | Farmaceutski preparat koji sadrži atorvastatin i antihipertenzivni agens |
Country Status (41)
| Country | Link |
|---|---|
| US (2) | US20020099046A1 (sh) |
| EP (1) | EP1009400B1 (sh) |
| JP (2) | JP2001514223A (sh) |
| KR (3) | KR20010022477A (sh) |
| CN (3) | CN1473567A (sh) |
| AP (1) | AP1191A (sh) |
| AR (1) | AR016399A1 (sh) |
| AT (1) | ATE285767T1 (sh) |
| AU (1) | AU740424B2 (sh) |
| BG (1) | BG64724B1 (sh) |
| BR (1) | BR9811556A (sh) |
| CA (1) | CA2296723A1 (sh) |
| CO (1) | CO4970724A1 (sh) |
| DE (1) | DE69828413T2 (sh) |
| DZ (1) | DZ2595A1 (sh) |
| EA (1) | EA200000012A1 (sh) |
| EG (1) | EG24678A (sh) |
| ES (1) | ES2234134T3 (sh) |
| GT (1) | GT199800126A (sh) |
| HR (1) | HRP980474A2 (sh) |
| HU (1) | HUP0004318A3 (sh) |
| ID (1) | ID24118A (sh) |
| IL (2) | IL133962A0 (sh) |
| IS (1) | IS5341A (sh) |
| MA (1) | MA26536A1 (sh) |
| MY (1) | MY121008A (sh) |
| NO (1) | NO323987B1 (sh) |
| NZ (2) | NZ502280A (sh) |
| OA (1) | OA11291A (sh) |
| PA (1) | PA8457901A1 (sh) |
| PE (1) | PE107099A1 (sh) |
| PL (1) | PL339091A1 (sh) |
| PT (1) | PT1009400E (sh) |
| SA (1) | SA98190603B1 (sh) |
| SK (1) | SK1432000A3 (sh) |
| TN (1) | TNSN98155A1 (sh) |
| TR (1) | TR200000563T2 (sh) |
| UY (1) | UY25155A1 (sh) |
| WO (1) | WO1999011260A1 (sh) |
| YU (1) | YU2000A (sh) |
| ZA (1) | ZA987839B (sh) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0656786B2 (en) | 1992-05-19 | 2014-04-23 | Novogen Research Pty Ltd | Use of isoflavone phyto-oestrogen extracts of soy or clover |
| US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| AUPO203996A0 (en) | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
| GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
| EP1063991A1 (en) * | 1998-03-17 | 2001-01-03 | Warner-Lambert Company Llc | Statin-matrix metalloproteinase inhibitor combinations |
| WO2000038721A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
| AU2007200367B2 (en) * | 1999-02-06 | 2010-04-08 | Astrazeneca Ab | Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
| GB0001662D0 (en) | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
| DK1216038T3 (da) | 1999-08-30 | 2005-12-27 | Sanofi Aventis Deutschland | Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser |
| AUPQ266199A0 (en) | 1999-09-06 | 1999-09-30 | Novogen Research Pty Ltd | Compositions and therapeutic methods involving isoflavones and analogues thereof |
| DE19944803A1 (de) * | 1999-09-20 | 2001-03-29 | Bayer Ag | Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
| WO2001022976A2 (en) | 1999-09-24 | 2001-04-05 | Vasogen Ireland Limited | Combination of a statin and ex-vivo treated blood for treating artheroclerosis |
| FR2803525B1 (fr) * | 2000-01-06 | 2002-05-03 | Sod Conseils Rech Applic | Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle |
| AR030414A1 (es) * | 2000-04-03 | 2003-08-20 | Astrazeneca Ab | Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos |
| GB2361185A (en) | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
| SE0002354D0 (sv) * | 2000-06-22 | 2000-06-22 | Astrazeneca Ab | New formulation |
| AR032758A1 (es) | 2000-07-19 | 2003-11-26 | Novartis Ag | Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos |
| AU2001284413A1 (en) * | 2000-08-30 | 2002-03-13 | Sankyo Company Limited | Medicinal compositions for preventing or treating heart failure |
| US7018649B2 (en) * | 2000-10-23 | 2006-03-28 | Euro-Celtique, S.A. | Felodipine transdermal device and methods |
| US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| AUPR255401A0 (en) * | 2001-01-16 | 2001-02-08 | Novogen Research Pty Ltd | Regulation of lipids and/or bone density and compositions therefor |
| HU230253B1 (hu) | 2001-01-26 | 2015-11-30 | Merck Sharp & Dohme Corp | Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| DK1355644T3 (da) | 2001-01-26 | 2006-10-23 | Schering Corp | Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi |
| AUPR363301A0 (en) | 2001-03-08 | 2001-04-05 | Novogen Research Pty Ltd | Dimeric isoflavones |
| US20030149010A1 (en) * | 2001-07-19 | 2003-08-07 | Keller Bradley T. | Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor |
| PE20030324A1 (es) * | 2001-07-31 | 2003-04-03 | Warner Lambert Co | Composiciones farmaceuticas de amlodipina y atorvastatina |
| US6852737B2 (en) * | 2001-08-06 | 2005-02-08 | Recordati Ireland Limited | Crude and crystalline forms of lercanidipine hydrochloride |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| JP2005504091A (ja) | 2001-09-21 | 2005-02-10 | シェーリング コーポレイション | ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置 |
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| US6852753B2 (en) | 2002-01-17 | 2005-02-08 | Pharmacia Corporation | Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake |
| CA2490636A1 (en) * | 2002-06-20 | 2003-12-31 | The Governors Of The University Of Alberta | Dichloroacetate in combination with cardioprotective or hemodynamic drugs |
| JP2005533822A (ja) * | 2002-06-27 | 2005-11-10 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | 臭化水素酸カルベジロール |
| MXPA04012923A (es) * | 2002-06-27 | 2005-03-31 | Sb Pharmco Inc | Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento. |
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| GB0221579D0 (en) * | 2002-09-17 | 2002-10-23 | Pfizer Ltd | Combinations of atorvastatin and, adrenergic receptor antagonists |
| JP2006504800A (ja) * | 2002-10-16 | 2006-02-09 | レコーダチ アイルランド リミテッド | リシノプリル／レルカニジピンの組み合わせ治療 |
| WO2004043457A1 (en) | 2002-11-06 | 2004-05-27 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| JP4589919B2 (ja) | 2003-03-07 | 2010-12-01 | シェーリング コーポレイション | 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用 |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| JP2006519869A (ja) | 2003-03-07 | 2006-08-31 | シェーリング コーポレイション | 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用 |
| CA2517571C (en) | 2003-03-07 | 2011-07-05 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| EP1686967A4 (en) * | 2003-11-25 | 2012-08-08 | Smithkline Beecham Cork Ltd | CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES |
| CA2547137A1 (en) * | 2003-11-25 | 2005-06-09 | Sb Pharmco Puerto Rico Inc. | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
| JP2007512372A (ja) * | 2003-11-25 | 2007-05-17 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | カルベジロール塩、対応する組成物、送達および／または治療方法 |
| KR20050092519A (ko) * | 2004-03-16 | 2005-09-22 | 화이자 인코포레이티드 | 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합 |
| US20070191438A1 (en) * | 2004-04-06 | 2007-08-16 | Rohrer Susan P | Methods for the treatment of hypertension |
| DE602005025755D1 (de) | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
| ES2342090T3 (es) * | 2004-08-25 | 2010-07-01 | Essentialis, Inc. | Formulaciones farmaceuticas de agentes de apertura de canales de potasio dependientes de atp y usos de los mismos. |
| BRPI0607142A2 (pt) * | 2005-02-17 | 2009-08-11 | Chiesi Farma Spa | combinações terapêuticas de manidipina e uma estatina, seu uso e um kit |
| EP2000137B1 (en) * | 2006-03-29 | 2015-10-21 | Kowa Company, Ltd. | Triglyceride-lowering agent and hyperinsulinism-ameliorating agent |
| US8642083B2 (en) * | 2006-10-30 | 2014-02-04 | Hanall Biopharma Co., Ltd. | Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors |
| KR101209319B1 (ko) | 2008-04-29 | 2012-12-06 | 한올바이오파마주식회사 | 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제 |
| CZ2008740A3 (cs) * | 2008-11-24 | 2010-01-06 | Zentiva, A.S. | Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem |
| MA33056B1 (fr) * | 2009-01-23 | 2012-02-01 | Hanmi Holding Co Ltd | Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication |
| SI23149A (sl) * | 2009-09-21 | 2011-03-31 | Silverstone Pharma | Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni |
| RU2481124C1 (ru) * | 2011-10-27 | 2013-05-10 | Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" | Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения |
| CN102671198A (zh) * | 2011-12-17 | 2012-09-19 | 东莞达信生物技术有限公司 | 一种降压降脂复方药及其制备方法 |
| KR20140028971A (ko) * | 2012-08-31 | 2014-03-10 | 한미약품 주식회사 | 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제 |
| JP2016514125A (ja) * | 2013-03-12 | 2016-05-19 | エルジー・ライフ・サイエンシーズ・リミテッドＬＧ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | バルサルタン及びロスバスタチンカルシウムを含む複合製剤及びその製造方法 |
| CN104173420A (zh) * | 2013-05-20 | 2014-12-03 | 广州诺氏刘生物科技有限公司 | 一种治疗急性肾衰竭的药物 |
| US10537546B2 (en) | 2014-10-23 | 2020-01-21 | Arena Pharmaceuticals, Inc. | Method of treating conditions related to the PGI2 receptor |
| RU2724338C2 (ru) * | 2015-06-30 | 2020-06-23 | Ханми Фарм. Ко., Лтд. | Фармацевтическая комплексная композиция, включающая амлодипин, лозартан и розувастатин |
| FR3040303B1 (fr) * | 2015-08-27 | 2019-04-05 | Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger | Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca |
| CN105232555A (zh) * | 2015-11-19 | 2016-01-13 | 哈尔滨圣吉药业股份有限公司 | 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法 |
| AU2017274438A1 (en) * | 2016-06-02 | 2018-12-13 | Ana Pharmaceuticals, Inc. | Methods and compositions for treatment of hypercalciuria and nephrolithiasis |
| SI4101454T1 (sl) | 2017-01-25 | 2024-10-30 | The George Institute for Global Health | Sestavki za uporabo pri zdravljenju hipertenzije |
| US12521380B2 (en) | 2017-01-25 | 2026-01-13 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| IL268997B2 (en) | 2017-03-01 | 2023-09-01 | Arena Pharm Inc | Preparations containing pgi2 receptor agonists and processes for their preparation |
| EP3796902A1 (en) | 2018-05-16 | 2021-03-31 | Arena Pharmaceuticals, Inc. | Compositions comprising pgi2-receptor agonists and processes for the preparation thereof |
| AU2019309329B2 (en) * | 2018-07-26 | 2025-01-30 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| CN112826937B (zh) * | 2021-03-25 | 2022-03-22 | 山东大学齐鲁医院 | 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5447922A (en) * | 1994-08-24 | 1995-09-05 | Bristol-Myers Squibb Company | α-phosphonosulfinic squalene synthetase inhibitors |
| IL118778A (en) * | 1995-07-03 | 1999-07-14 | Sankyo Co | Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor |
| AU720853B2 (en) * | 1995-11-02 | 2000-06-15 | Warner-Lambert Company | Method and pharmaceutical composition for regulating lipid concentration |
-
1998
- 1998-08-07 GT GT199800126A patent/GT199800126A/es unknown
- 1998-08-11 TR TR2000/00563T patent/TR200000563T2/xx unknown
- 1998-08-11 IL IL13396298A patent/IL133962A0/xx not_active IP Right Cessation
- 1998-08-11 EA EA200000012A patent/EA200000012A1/ru unknown
- 1998-08-11 CA CA002296723A patent/CA2296723A1/en not_active Abandoned
- 1998-08-11 WO PCT/IB1998/001230 patent/WO1999011260A1/en not_active Ceased
- 1998-08-11 CN CNA031430937A patent/CN1473567A/zh active Pending
- 1998-08-11 CN CN98808463A patent/CN1268053A/zh active Pending
- 1998-08-11 KR KR1020007001062A patent/KR20010022477A/ko not_active Ceased
- 1998-08-11 KR KR10-2003-7000672A patent/KR20030015394A/ko not_active Ceased
- 1998-08-11 AT AT98935250T patent/ATE285767T1/de not_active IP Right Cessation
- 1998-08-11 HU HU0004318A patent/HUP0004318A3/hu unknown
- 1998-08-11 JP JP2000508363A patent/JP2001514223A/ja not_active Withdrawn
- 1998-08-11 PL PL98339091A patent/PL339091A1/xx unknown
- 1998-08-11 CN CNA031430929A patent/CN1473566A/zh active Pending
- 1998-08-11 NZ NZ502280A patent/NZ502280A/xx unknown
- 1998-08-11 NZ NZ530630A patent/NZ530630A/en unknown
- 1998-08-11 YU YU2000A patent/YU2000A/sh unknown
- 1998-08-11 AU AU84589/98A patent/AU740424B2/en not_active Ceased
- 1998-08-11 ID IDW20000196A patent/ID24118A/id unknown
- 1998-08-11 BR BR9811556-1A patent/BR9811556A/pt not_active Application Discontinuation
- 1998-08-11 PT PT98935250T patent/PT1009400E/pt unknown
- 1998-08-11 DE DE69828413T patent/DE69828413T2/de not_active Expired - Fee Related
- 1998-08-11 KR KR10-2004-7019432A patent/KR20040106591A/ko not_active Ceased
- 1998-08-11 ES ES98935250T patent/ES2234134T3/es not_active Expired - Lifetime
- 1998-08-11 SK SK143-2000A patent/SK1432000A3/sk unknown
- 1998-08-11 EP EP98935250A patent/EP1009400B1/en not_active Expired - Lifetime
- 1998-08-17 PA PA19988457901A patent/PA8457901A1/es unknown
- 1998-08-24 PE PE1998000769A patent/PE107099A1/es not_active Application Discontinuation
- 1998-08-26 MA MA25228A patent/MA26536A1/fr unknown
- 1998-08-26 TN TNTNSN98155A patent/TNSN98155A1/fr unknown
- 1998-08-26 UY UY25155A patent/UY25155A1/es not_active Application Discontinuation
- 1998-08-26 DZ DZ980205A patent/DZ2595A1/xx active
- 1998-08-27 AR ARP980104287A patent/AR016399A1/es unknown
- 1998-08-27 EG EG102598A patent/EG24678A/xx active
- 1998-08-27 CO CO98049139A patent/CO4970724A1/es unknown
- 1998-08-27 MY MYPI98003941A patent/MY121008A/en unknown
- 1998-08-27 AP APAP/P/1998/001332A patent/AP1191A/en active
- 1998-08-28 HR HR60/057,276A patent/HRP980474A2/hr not_active Application Discontinuation
- 1998-08-28 ZA ZA9807839A patent/ZA987839B/xx unknown
- 1998-09-30 SA SA98190603A patent/SA98190603B1/ar unknown
-
2000
- 2000-01-09 IL IL133962A patent/IL133962A/en unknown
- 2000-01-13 BG BG104075A patent/BG64724B1/bg unknown
- 2000-01-14 IS IS5341A patent/IS5341A/is unknown
- 2000-02-18 OA OA1200000040A patent/OA11291A/en unknown
- 2000-02-28 NO NO20000996A patent/NO323987B1/no unknown
-
2001
- 2001-10-23 US US10/045,329 patent/US20020099046A1/en not_active Abandoned
-
2003
- 2003-05-19 US US10/442,285 patent/US20030199492A1/en not_active Abandoned
-
2004
- 2004-07-22 JP JP2004214382A patent/JP2005041875A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU2000A (sh) | Farmaceutski preparat koji sadrži atorvastatin i antihipertenzivni agens | |
| MY123993A (en) | Therapeutic combinations | |
| CA2296726A1 (en) | Combination therapy | |
| WO1998033491A3 (en) | Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase | |
| IL132853A0 (en) | Combination therapy for modulating the human sexual response | |
| ES2175437T3 (es) | Composicion de enalapril y losartan. | |
| WO1998042650A3 (en) | Leukotriene antagonists useful for treating cystic fibrosis | |
| ECSP982647A (es) | Terapia de combinacion | |
| ECSP982645A (es) | Terapia de combinacion | |
| ECSP982646A (es) | Combinaciones terapeuticas | |
| AU6920398A (en) | Medicament for preventive and therapeutic treatment of inflammatory diseas es |